MNTA  Momenta Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

761.45M

Vuru Grade

31.00/100

Current Price

$11.14
+0.24 (+2.20%)

Company Metrics

  • P/E 13.83
  • P/S 7.38
  • P/B 2.12
  • EPS -1.28
  • Cash ROIC -52.09%
  • Cash Ratio 9.03
  • Dividend 0 / 0%
  • Avg. Vol. 573,467.00
  • Shares 68.35M
  • Market Cap. 761.45M

Company Description

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development of generic versions of complex drug products, as well as for th... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Momenta Pharmaceuticals Inc. Shed a Third of Its Value in February -- Here's Why
Motley Fool - Mar 4, 2016
What: Shares of Momenta Pharmaceuticals (NASDAQ:MNTA), a biopharmaceutical company focused on the development of generic and biosimilar drugs for oncology and autoimmune diseases, shed 33% of their value in February, based on data from S&P ...
Why Momenta Pharmaceuticals, Inc. Earned a Lower Price Today
Motley Fool - Feb 18, 2016
What: Momenta Pharmaceuticals (NASDAQ:MNTA) is down 11% at 12:00 p.m. EST Thursday after releasing fourth quarter earnings this morning.
Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler on Q4 2015 Results ... - Seeking Alpha
Momenta Pharmaceuticals' losses spark slide - Proactive Investors USA & Canada
Why Momenta Pharmaceuticals, Inc. Was Up Today
Motley Fool - Jan 8, 2016
What: Momenta Pharmaceuticals (NASDAQ:MNTA) was up as much as much as 11.7% today, eventually finishing up 6.8% after announcing a deal with Mylan (NASDAQ:MYL) to develop six biosimilar products.
Momenta, Mylan to Jointly Develop Six Biosimilars - Wall Street Journal
Mylan to collaborate with Momenta to develop biosimilar products in $245M deal - Pittsburgh Business Times (blog)
Momenta Pharmaceuticals Incorporated (NASDAQ:MNTA) Sellers Increased By 6.65 ...
Franklin Independent - 18 hours ago
Momenta Pharmaceuticals, Inc. is a biotechnology company. The company has a market cap of $807.40 million. The Firm is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease.
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Closes At $10.90 - Vanguard Tribune
New Analyst Ratings On Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) - Risers & Fallers
Broker Changes For Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)
Risers & Fallers - May 26, 2016
Recently stock market analysts have updated their consensus ratings on shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA).
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Reports Yearly Sales Estimate At ... - Vanguard Tribune
Here's Why Momenta Pharmaceuticals, Inc. Shares Took Off Today
Motley Fool - Jun 1, 2015
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib ... - GlobeNewswire (press release)
An Insider James Roach Sold 1092 shares of Momenta Pharmaceuticals, Inc ...
Franklin Independent - May 23, 2016
James Roach; that is an insider in Momenta Pharmaceuticals Inc who is the most recent to unload shares in the firm for which he serves as a Senior VP - Development and Chi.
After Last Week What Do Analysts Think Of Momenta Pharmaceuticals, Inc ... - Share Trading News
Momenta Pharmaceuticals Inc. (MNTA) Jumps 7.15% on May 09
Equities.com - May 9, 2016
Momenta Pharmaceuticals Inc. (MNTA) was among the biggest gainers on the Russell 2000 for Monday May 09 as the stock popped 7.15% to $10.04, representing a gain of $0.67 per share.
Brean Capital Reaffirms "Buy" Rating for Momenta Pharmaceuticals, Inc. (MNTA) - NewsWay 21
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Analyst Review - Risers & Fallers
Momenta Pharmaceuticals Inc. (MNTA) Drops 5.84% on May 03
Equities.com - May 5, 2016
Momenta Pharmaceuticals Inc. (MNTA) was one of the Russell 2000's biggest losers for Tuesday May 03 as the stock slid 5.84% to $9.19, a loss of $-0.57 per share.
Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 37th ...
Nasdaq - May 25, 2016
CAMBRIDGE, Mass., May 25, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that its presentation at the ...
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Closes At $10.97 - Enterprise Leader